Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall
Moyer, Ann M. , Yu, Jia , Sinnwell, Jason P. , Dockter, Travis , Weinshilboum, Richard M. , Visscher, Daniel W., Wang, Liewei , Dockter, Travis J, Sinnwell, Jason P , Suman, Vera J. , Weinshilboum, Richard M. , Boughey, Judy C. , Goetz, Matthew P.

Mayo Clinic

Oncotarget | June 11, 2019 | Volume: 10 | Issue: 39 | Pages: 3924-3930

10.18632/oncotarget.27001 | PMID 31231469 Get It

Strength and Function Across Maturational Levels in Young Athletes at the Time of Return to Sport After ACL Reconstruction
Paljieg, Adam, Thomas, Staci , Hewett, Timothy E. , Paterno, Mark V. , Schmitt, Laura C. , Ithurburn, Matthew P.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | June 7, 2019 | Volume: 11 | Issue: 4 | Pages: 324-331

10.1177/1941738119849070 | PMID 31173697 Get It

Background: The impact of maturation on lower extremity strength and function after anterior cruciate ligament reconstruction (ACLR) may help guide future studies of age-specific rehabilitation. Hypothesis Pediatric ACLR patients would demonstrate higher thigh strength symmetry and knee-related function at return to sport (RTS) compared with adolescent and young adult participants who underwent traditional ACLR. Study Design: Prospective cohort study. Level of Evidence: Level 2. Methods: A total of 144 young athletes at the time of RTS clearance post-ACLR were classified into 3 maturational groups (pediatric, n = 16 with physeal-sparing ACLR [mean age = 12.3 years; range = 9.2-14.6 years]; adolescent, n = 113 [mean age = 16.5 years; range = 14.1-19.8 years]; young adult, n = 15 [mean age = 22.0 years; range = 20.5-24.9 years]). Quadriceps and hamstring strength were measured using an electromechanical dynamometer. Knee-related function was measured using the International Knee Documentation Committee (IKDC) subjective form and single-leg hop tests. The Limb symmetry Index (LSI) was used in calculations for hop and strength tests. Group differences were compared with Kruskal-Wallis tests and Mann-Whitney U post hoc tests. Proportions of participants meeting literature-recommended RTS criterion cutoffs were compared among the groups using chi-square tests. Results: The pediatric group demonstrated higher quadriceps LSI ( P = 0.01), IKDC scores ( P < 0.01), single-hop LSI ( P < 0.01), and crossover-hop LSI ( P = 0.02) compared with the young adult group. In addition, the pediatric group demonstrated higher IKDC scores ( P < 0.01) and single-hop LSI ( P = 0.02) compared with the adolescent group. The adolescent group demonstrated higher IKDC scores ( P < 0.01), single-hop LSI ( P = 0.02), and crossover-hop LSI ( P = 0.03) compared with the young adult group. The proportions of participants meeting all RTS criterion cutoffs were highest in the pediatric group and lowest in the young adult group ( P = 0.03). Conclusion: Young athletes at RTS clearance after pediatric ACLR demonstrated higher quadriceps strength symmetry and knee-related function than adolescents and young adults after traditional ACLR. Clinical Relevance: These findings demonstrate the need for further study regarding the impact of these group differences on longitudinal outcomes after ACLR, including successful RTS and risk of second ACL injury.
Murine T Cell Maturation Entails Protection from MBL2, but Complement Proteins Do Not Drive Clearance of Cells That Fail Maturation in the Absence of NKAP
Dash, Barsha, Belmonte, Paul , Fine, Sydney R. , Shapiro, Michael J. , Chung, Ji Young, Schwab, Aaron , McCue, Shaylene , Rajcula, Matthew, Shapiro, Virginia Smith , Belmonte, Paul J , Schwab, Aaron D, Shapiro, Virginia S , Schwab, Aaron D , Shapiro, Michael Jeremy

Mayo Clinic

The Journal of Immunology | June 7, 2019 | Volume: 203 | Issue: 2 | Pages: 408-417

10.4049/jimmunol.1801443 | PMID 31175160 Get It

Abstract Recent thymic emigrants that fail postpositive selection maturation are targeted by complement proteins. T cells likely acquire complement resistance during maturation in the thymus, a complement-privileged organ. To test this, thymocytes and fresh serum were separately obtained and incubated together in vitro to assess complement deposition. Complement binding decreased with development and maturation. Complement binding decreased from the double-positive thymocyte to the single-positive stage, and within single-positive thymocytes, complement binding gradually decreased with increasing intrathymic maturation. Binding of the central complement protein C3 to wild-type immature thymocytes required the lectin but not the classical pathway. Specifically, MBL2 but not MBL1 was required, demonstrating a unique function for MBL2. Previous studies demonstrated that the loss of NKAP, a transcriptional regulator of T cell maturation, caused peripheral T cell lymphopenia and enhanced complement susceptibility. To determine whether complement causes NKAP-deficient T cell disappearance, both the lectin and classical pathways were genetically ablated. This blocked C3 deposition on NKAP-deficient T cells but failed to restore normal cellularity, indicating that complement contributes to clearance but is not the primary cause of peripheral T cell lymphopenia. Rather, the accumulation of lipid peroxides in NKAP-deficient T cells was observed. Lipid peroxidation is a salient feature of ferroptosis, an iron-dependent nonapoptotic cell death. Thus, wild-type thymocytes naturally acquire the ability to protect themselves from complement targeting by MBL2 with maturation. However, NKAP-deficient immature peripheral T cells remain scarce in complement-deficient mice likely due to ferroptosis.
Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study
D’Costa, Matthew R. , Haley, William E. , Mara, Kristin C. , Vrtiska, Terri J., Pais, Vernon M., Jacobsen, Steven J. , Rule, Andrew D. , Rule, Andrew D , Haley, William E , D'Costa, Matthew , Mara, Kristin C , Enders, Felicity , McCollough, Cynthia H. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | June 7, 2019 | Volume: 30 | Issue: 7 | Pages: 1251-1260

10.1681/asn.2018121241 | PMID 31175141 Get It

Significance Statement Kidney stone recurrence can manifest with symptoms from stone passage or with asymptomatic changes in kidney stone burden revealed by radiography. In a multicenter, prospective cohort study, the authors demonstrate that substantially more asymptomatic and self-managed symptomatic kidney stone recurrence occur in stone formers than has been appreciated, as many studies consider only symptomatic recurrence that results in clinical care. Among first-time symptomatic stone formers, 54% had an asymptomatic kidney stone; half of those with such a stone passed it within 5 years (but only half who did so experienced symptoms). The findings also show that when a more comprehensive definition of recurrence that includes all symptomatic and radiological manifestations is used, risk factors better predict kidney stone recurrence, thus supporting a comprehensive assessment of recurrence in clinical trials. Background Meaningful interpretation of changes in radiographic kidney stone burden requires understanding how radiographic recurrence relates to symptomatic recurrence and how established risk factors predict these different manifestations of recurrence. Methods We recruited first-time symptomatic stone formers from the general community in Minnesota and Florida. Baseline and 5-year follow-up study visits included computed tomography scans, surveys, and medical record review. We noted symptomatic recurrence detected by clinical care (through chart review) or self-report, and radiographic recurrence of any new stone, stone growth, or stone passage (comparing baseline and follow-up scans). To assess the prediction of different manifestations of recurrence, we used the Recurrence of Kidney Stone (ROKS) score, which sums multiple baseline risk factors. Results Among 175 stone formers, 19% had symptomatic recurrence detected by clinical care and 25% detected by self-report; radiographic recurrence manifested as a new stone in 35%, stone growth in 24%, and stone passage in 27%. Among those with a baseline asymptomatic stone (54%), at 5 years, 51% had radiographic evidence of stone passage (accompanied by symptoms in only 52%). Imaging evidence of a new stone or stone passage more strongly associated with symptomatic recurrence detected by clinical care than by self-report. The ROKS score weakly predicted one manifestation—symptomatic recurrence resulting in clinical care ( c -statistic, 0.63; 95% confidence interval, 0.52 to 0.73)—but strongly predicted any manifestation of symptomatic or radiographic recurrence (5-year rate, 67%; c -statistic, 0.79; 95% confidence interval, 0.72 to 0.86). Conclusions Recurrence after the first stone episode is both more common and more predictable when all manifestations of recurrence (symptomatic and radiographic) are considered.
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Farooq, Umar , Link, Brian K. , King, Rebecca L. , Allmer, Cristine, Thompson, Carrie A. , Micallef, Ivana N. , Johnston, Patrick B. , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Link, Brian K , Farooq, Umar , Wang, Yucai , Larson, Melissa C. , Maurer, Matthew J. , Hefazi, Mehrdad , Habermann, Thomas M. , Witzig, Thomas E. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2019 | Volume: 37 | Issue: 21 | Pages: 1819-1827

10.1200/jco.19.00014 | PMID 31170029 Get It

PURPOSE In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur within the first 2 years of diagnosis. We sought to define the rate and outcome of late relapses that occurred after achieving event-free survival at 24 months (EFS24). METHODS We prospectively followed 1,324 patients with newly diagnosed DLBCL from 2002 to 2015 and treated with immunochemotherapy. Cumulative incidences of late DLBCL and indolent lymphoma relapses were analyzed as competing events. Postrelapse survival was defined as time from first relapse to death from any cause. RESULTS In 847 patients who achieved EFS24, the cumulative incidence of late relapse was 6.9% at 3 years, 9.3% at 5 years, and 10.3% at 8 years after EFS24. The incidence of DLBCL relapse was similar in patients with DLBCL alone at diagnosis (6.3% at 5 years), compared with patients with concurrent indolent lymphoma at diagnosis (5.2%; P = .46). However, the rate of indolent lymphoma relapse was higher in patients with concurrent indolent lymphoma (7.4% v 2.1% at 5 years; P < .01). In patients with DLBCL alone, the rate of DLBCL relapse was similar in the germinal center B-cell–like (GCB) (4.1% at 5 years) and non-GCB (4.0%; P = .71) subtypes, whereas the rate of indolent lymphoma relapse was higher in patients with the GCB subtype (3.9% v 0.0% at 5 years; P = .02). Postrelapse survival was inferior for patients who relapsed with DLBCL than for those who relapsed with indolent lymphoma (median 29.9 months v unreached; P < .01). CONCLUSION Patients with DLBCL with a concurrent indolent lymphoma and those with the GCB subtype had a higher rate of late relapse, owing to increased relapses with indolent lymphoma. Patients who relapsed with DLBCL had a worse prognosis than those who relapsed with indolent lymphoma.
Adenoviral gene transfer of a single‐chain IL‐23 induces psoriatic arthritis–like symptoms in NOD mice
Flores, Rafael R. , Carbo, Lana, Meter, Montina Van, Padilla, Consuelo M. López de , Zhao, Jing , Colangelo, Debora , Yousefzadeh, Negar , Angelini, Luise, Zhang, Lei , Pola, Enrico , Evans, Christopher H. , Gambotto, Andrea , Niedernhofer, Laura J. , Robbins, Paul D. , De Padilla, Consuelo M Lopez, Niedernhofer, Laura J , Robbins, Paul D , Zhang, Lei , Kim, Eun Young , Yousefzadeh, Matthew J., Vo, Nam

Mayo Clinic

The FASEB Journal | June 6, 2019 | Volume: 33 | Issue: 8 | Pages: 9505-9515

10.1096/fj.201900420r | PMID 31170010 Get It

ABSTRACT Previously, we demonstrated that intratumoral delivery of adenoviral vector encoding single‐chain (sc) IL‐23 (Ad.scIL‐23) was able to induce systemic antitumor immunity. Here, we examined the role of IL‐23 in diabetes in nonobese diabetic mice. Intravenous delivery of Ad.scIL‐23 did not accelerate the onset of hyperglycemia but instead resulted in the development of psoriatic arthritis. Ad.scIL‐23–treated mice developed erythema, scales, and thickening of the skin, as well as intervertebral disc degeneration and extensive synovial hypertrophy and loss of articular cartilage in the knees. Immunological analysis revealed activation of conventional T helper type 17 cells and IL‐17–producing γδ T cells along with a significant depletion and suppression of T cells in the pancreatic lymph nodes. Furthermore, treatment with anti–IL‐17 antibody reduced joint and skin psoriatic arthritis pathologies. Thus, these Ad.scIL‐23–treated mice represent a physiologically relevant model of psoriatic arthritis for understanding disease progression and for testing therapeutic approaches.—Flores, R. R., Carbo, L., Kim, E., Van Meter, M., De Padilla, C. M. L., Zhao, J., Colangelo, D., Yousefzadeh, M. J., Angelini, L. A., Zhang, L., Pola, E., Vo, N., Evans, C. H., Gambotto, A., Niedernhofer, L. J., Robbins, P. D. Adenoviral gene transfer of a single‐chain IL‐23 induces psoriatic arthritis–like symptoms in NOD mice. FASEB J. 33, 9505–9515 (2019). www.fasebj.org
Total Knee Arthroplasty After High Tibial Osteotomy Results in Excellent Long-Term Survivorship and Clinical Outcomes
Chalmers, Brian P. , Limberg, Afton K. , Tibbo, Meagan E. , Perry, Kevin I. , Pagnano, Mark W. , Abdel, Matthew P. , Abdel, Matthew P

Mayo Clinic

Journal of Bone and Joint Surgery | June 6, 2019 | Volume: 101 | Issue: 11 | Pages: 970-978

10.2106/jbjs.18.01060 | PMID 31169573 Get It

Background: Some prior reports of total knee arthroplasty after high tibial osteotomy have shown high rates of aseptic loosening. As such, the goal of this study was to analyze the outcomes of contemporary total knee arthroplasty after high tibial osteotomy, with particular emphasis on survivorship free from aseptic loosening, any revision, and any reoperation; complications; radiographic results; and clinical outcomes. Methods: We retrospectively reviewed 207 patients who underwent 231 total knee arthroplasties using cemented prostheses after high tibial osteotomy from 2000 to 2012 through our total joint registry: 87% were after a closing-wedge osteotomy and 13% were after an opening-wedge osteotomy. The mean follow-up from total knee arthroplasty was 8 years. At the time of the total knee arthroplasty, the mean age was 64 years and the mean body mass index was 31 kg/m 2 . The majority of total knee arthroplasties had a posterior-stabilized design (93%), and 4% had a varus-valgus constraint design. Tibial stems were utilized in 8% of cases. Bivariate and multivariate Cox regression analyses were utilized to analyze risk factors for poorer survival. Results: At 10 years, survivorship free from aseptic loosening was 97%, survivorship free from any revision was 90%, and survivorship free from any reoperation was 85%. Fifteen patients (15 total knee arthroplasties [6%]) underwent aseptic revision, most commonly for instability (3%), aseptic loosening (2%), and periprosthetic fracture (1%). On bivariate analysis, patient age of <60 years was a significant risk factor for poorer revision-free survival (hazard ratio, 2.9; p = 0.02); on multivariate analysis, younger age was the only significant risk factor for revision (p = 0.04). There were 14 complications (6%), the most common being a manipulation under anesthesia in 9 cases (4%). No unrevised total knee arthroplasties had definitive radiographic evidence of loosening. Knee Society scores improved from a mean preoperative score of 59 points to a mean postoperative score of 93 points (p < 0.001). Conclusions: Contemporary total knee arthroplasty with a cemented prosthesis after high tibial osteotomy demonstrated excellent long-term durability, with 10-year survivorship free from aseptic loosening of 97%. There was reliable improvement in clinical outcomes, but perfect knee balance was sometimes challenging, as reflected by a 4% prevalence of manipulation under anesthesia and a 3% prevalence of revision for instability. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy
Hunt, Katie N. , Conners, Amy Lynn , O’Connor, Michael K. , Weinshilboum, Richard, Wang, Liewei , Carter, Jodi M. , McLaughlin, Sarah A. , Aspitia, Alvaro Moreno, Gray, Richard J. , Northfelt, Don W., O'Connor, Michael K, Suman, Vera, Kalari, Krishna, Carter, Jodi, Northfelt, Don, Goetz, Matthew P. , Suman, Vera J. , Kalari, Krishna R. , Boughey, Judy C. , Carter, Jodi

Mayo Clinic

American Journal of Roentgenology | June 5, 2019 | Volume: 213 | Issue: 4 | Pages: 932-943

10.2214/ajr.18.20628 | PMID 31166752 Get It

Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, Val J. , Lundt, Emily S. , Albertson, Sabrina M., Przybelski, Scott A. , Senjem, Matthew L. , Parisi, Joseph E., Kantarci, Kejal , Jack, Clifford R. , Petersen, Ronald C. , Murray, Melissa E. , Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Murray, Melissa E , Boeve, Bradley F. , Jones, David T. , Knopman, David S. , Dickson, Dennis W. , Lundt, Emily S

Mayo Clinic

Alzheimer's & Dementia | June 4, 2019 | Volume: 15 | Issue: 7 | Pages: 927-939

10.1016/j.jalz.2019.03.016 | PMID 31175025 Get It

Abstract Introduction Neuroimaging biomarkers are important for early diagnosis of Alzheimer's disease, and comparing multimodality neuroimaging to autopsy data is essential. Methods We compared the pathologic findings from a prospective autopsy cohort (n = 100) to Pittsburgh compound B PET (PiB‐PET), 18 F‐fluorodeoxyglucose PET (FDG‐PET), and MRI. Correlations between neuroimaging biomarkers and neuropathologic schemes were assessed. Results PiB‐PET showed strong correlations with Thal amyloid phase and Consortium to Establish a Registry for Alzheimer's Disease score and categorized 44% of Thal phase 1 participants as positive. FDG‐PET and MRI correlated modestly with Braak tangle stage in Alzheimer's type pathology. A subset of participants with “none” or “sparse” neuritic plaque scores had elevated PiB‐PET signal due to diffuse amyloid plaque. Participants with findings characterized as “suspected non‐Alzheimer's pathophysiology” represented 15% of the group. Discussion PiB‐PET is associated with Alzheimer's disease, neuritic plaques, and diffuse plaques. FDG‐PET and MRI have modest correlation with neuropathologic schemes. Participants with findings characterized as suspected non‐Alzheimer's pathophysiology most commonly had primary age‐related tauopathy.
Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction
Lee, Justin Z. , Amin, Mustapha, Neville, Matthew R., Almader‐Douglas, Diana , Killu, Ammar M. , Madhavan, Malini , Cha, Yong‐Mei , Asirvatham, Samuel J. , Friedman, Paul A. , Mulpuru, Siva K. , Tseng, Andrew S. , Kunze, Katie L. , Almader-Douglas, Diana, Asirvatham, Samuel J , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | June 4, 2019 | Volume: 12 | Issue: 6 | Pages: No page available

10.1161/circep.118.006951 | PMID 31159582 Get It

Background: The treatment of heart failure with reduced ejection fraction has been the subject of numerous randomized controlled trials involving medications and cardiac implantable electronic device therapies. As newer effective pharmacological therapies suggest significant reductions in all-cause mortality, the role of additional device therapy in heart failure with reduced ejection fraction deserves further scrutiny. Methods: A systematic review and network meta-analysis on the effect of medication and device therapies in heart failure with reduced ejection fraction on all-cause mortality was performed. Randomized controlled trials published between January 1980 and July 2017 were identified using Medline, EMBASE, and Cochrane Controlled Register of Trials databases. Pcnetmeta package in R was used to calculate treatment arm–based estimated rates, rate ratios, and probability ranks with 95% credible intervals. Results: Combination therapy of ACE (angiotensin-converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) with β-blockers (BBs) alone or in addition to implantable cardiac defibrillators or cardiac resynchronization therapy with defibrillators demonstrated a significant reduction of all-cause mortality when compared with placebo. By probability rank, implantable cardiac defibrillator+ACE inhibitor or ARB+BB+mineralocorticoid receptor antagonist, implantable cardiac defibrillator+ACE inhibitor or ARB+BB, and angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist combination therapies have the highest probability of being ranked the best treatment. There was no significant difference in the rate of mortality when comparing angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist to implantable cardiac defibrillator+optimal pharmacological combination therapy. Conclusions: BB and renin-angiotensin system blockers alone or in combination with defibrillator device therapy have robust evidence for a reduction in mortality compared with placebo. The comparative efficacy of pharmacological therapy with angiotensin receptor-neprilysin inhibitors and device therapy deserves further investigation.